357 related articles for article (PubMed ID: 22138097)
1. Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer.
Hall PS; McCabe C; Stein RC; Cameron D
J Natl Cancer Inst; 2012 Jan; 104(1):56-66. PubMed ID: 22138097
[TBL] [Abstract][Full Text] [Related]
2. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
[TBL] [Abstract][Full Text] [Related]
3. Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor-positive, lymph-node-negative early-stage breast cancer in Japan.
Yamauchi H; Nakagawa C; Yamashige S; Takei H; Yagata H; Yoshida A; Hayashi N; Hornberger J; Yu T; Chao C; Yoshizawa C; Nakamura S
BMC Health Serv Res; 2014 Sep; 14():372. PubMed ID: 25190451
[TBL] [Abstract][Full Text] [Related]
4. Incorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis.
Wang SY; Chen T; Dang W; Mougalian SS; Evans SB; Gross CP
J Natl Compr Canc Netw; 2019 Jan; 17(1):39-46. PubMed ID: 30659128
[No Abstract] [Full Text] [Related]
5. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis.
Wolowacz SE; Cameron DA; Tate HC; Bagust A
J Clin Oncol; 2008 Feb; 26(6):925-33. PubMed ID: 18281666
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
[TBL] [Abstract][Full Text] [Related]
7. Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2020; 20(10):1-234. PubMed ID: 32284770
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
9. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
[TBL] [Abstract][Full Text] [Related]
10. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization.
Klang SH; Hammerman A; Liebermann N; Efrat N; Doberne J; Hornberger J
Value Health; 2010; 13(4):381-7. PubMed ID: 20412544
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in post-menopausal women with early-stage estrogen or progesterone-receptor-positive, axillary lymph-node positive breast cancer.
Hannouf MB; Xie B; Brackstone M; Zaric GS
Pharmacoeconomics; 2014 Feb; 32(2):135-47. PubMed ID: 24288208
[TBL] [Abstract][Full Text] [Related]
12. Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective.
Seguí MÁ; Crespo C; Cortés J; Lluch A; Brosa M; Becerra V; Chiavenna SM; Gracia A
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):889-99. PubMed ID: 25213317
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model.
Yang M; Rajan S; Issa AM
Cancer; 2012 Oct; 118(20):5163-70. PubMed ID: 22359236
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects.
Au HJ; Golmohammadi K; Younis T; Verma S; Chia S; Fassbender K; Jacobs P
Breast Cancer Res Treat; 2009 Apr; 114(3):579-87. PubMed ID: 18443903
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer.
Paulden M; Franek J; Pham B; Bedard PL; Trudeau M; Krahn M
Value Health; 2013; 16(5):729-39. PubMed ID: 23947965
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer.
Berdunov V; Millen S; Paramore A; Hall P; Perren T; Brown R; Griffin J; Reynia S; Fryer N; Longworth L
J Med Econ; 2022; 25(1):591-604. PubMed ID: 35416089
[TBL] [Abstract][Full Text] [Related]
18. A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the U.K.
Holt S; Bertelli G; Humphreys I; Valentine W; Durrani S; Pudney D; Rolles M; Moe M; Khawaja S; Sharaiha Y; Brinkworth E; Whelan S; Jones S; Bennett H; Phillips CJ
Br J Cancer; 2013 Jun; 108(11):2250-8. PubMed ID: 23695023
[TBL] [Abstract][Full Text] [Related]
19. A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands.
Simons MJHG; Machielsen PM; Spoorendonk JA; Ignacio T; Drost PB; Jacobs T; de Jongh FE
J Med Econ; 2024; 27(1):445-454. PubMed ID: 38436289
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]